Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
An anti-inflammatory and anti-allergic compound originally approved for treating aphthous ulcers (canker sores). Gained renewed interest after research showed it inhibits NNMT (nicotinamide N-methyltransferase) and IKKε/TBK1 kinases, pathways involved in obesity and insulin resistance. Being explored as a metabolic optimization compound alongside 5-Amino-1MQ.
A coenzyme found in all living cells that plays a central role in energy metabolism and cellular repair. NAD+ levels decline significantly with age. Injectable NAD+ and its precursors (NMN, NR) have become widely used in longevity and anti-aging protocols.
Inhibits IKKε (inhibitor of nuclear factor kappa-B kinase subunit epsilon) and TBK1 (TANK-binding kinase 1), which are upregulated in obesity and drive chronic low-grade inflammation and insulin resistance. Also inhibits NNMT, increasing NAD+ availability and energy expenditure. The combined effect improves insulin sensitivity and promotes fat oxidation.
Serves as an electron carrier in cellular respiration (ATP production). Activates sirtuins (SIRT1-7), a family of proteins involved in DNA repair, inflammation regulation, and metabolic homeostasis. Also activates PARP enzymes involved in DNA damage repair.
- Metabolic optimization research
- Insulin sensitivity improvement
- Fat loss support (investigational)
- Anti-inflammatory applications
- Aphthous ulcer treatment (original indication)
- Anti-aging and longevity protocols
- Energy and cognitive enhancement
- Addiction recovery support
- Athletic performance and recovery
- Metabolic health optimization
- Contact dermatitis at application site
- Nausea and diarrhea (oral use)
- Stinging or burning sensation (topical)
- Limited data for metabolic applications in humans
- Discontinued from US market (Aphthasol) — availability limited
- IV infusions can cause flushing, nausea, chest tightness (usually transient)
- Oral precursors (NMN, NR) generally well-tolerated
- Long-term effects of supraphysiological dosing unknown
- Theoretical concern: NAD+ may support cancer cell metabolism
- Quality varies significantly across suppliers
Previously FDA-approved as Aphthasol (topical paste for canker sores) but voluntarily withdrawn from the US market for commercial reasons (not safety). Not currently approved for metabolic indications. Available through compounding pharmacies and research suppliers.
NAD+ itself is not FDA-approved as a drug. Injectable NAD+ is available through compounding pharmacies with a prescription. Oral precursors (NMN, NR) are sold as dietary supplements. Not on any FDA compounding category list — exists in a separate regulatory framework from the peptides affected by the 2026 reclassification.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.